by Peter Ciszewski | Oct 5, 2021
Steven Cummings, MD, Executive Director of the San Francisco Coordinating Center talks about the important role that mobile research nurses have in conducting clinical trials remotely. Dr. Cummings is a lead investigator of the TOPAZ study, that involves assessing...
by Peter Ciszewski | Oct 4, 2021
Julie Dohm, PhD, JD, Of Counsel at Covington & Burling, discusses some of the risks associated with drug compounding, including uncertain ingredients, quality of how the compounds are made, labeling of drug, and untested formulas. Julie Dohm focuses on regulatory...
by Peter Ciszewski | Oct 4, 2021
Michael Panzara, MD, MPH, Chief Medical Officer at Wave Life Sciences, discusses the company’s clinical trial currently underway that is testing WVE-003 in adults with early stage Huntington disease. Huntington disease is an inherited, neurodegenerative...
by Peter Ciszewski | Oct 2, 2021
The U.S. Food and Drug Administration (FDA) has approved brexucabtagene autoleucel (Tecartus) for the treatment of adult patients (18 years and older) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). This is the second indication for...
by Peter Ciszewski | Oct 2, 2021
Lance Leopold, MD, Group Vice President, Immuno-Oncology, at Incyte, gives an overview of squamous cell carcinoma of the anal canal (SCAC). As Dr. Leopold explains, SCAC is a rare cancer in which malignant cells form in the cells that line the anus. This is the...
